TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CCTG 595: A Multicenter, Randomized Study of Text Messaging to Improve Adherence to PrEP in Risky MSM
Brief Summary: CCTG 595 is a controlled, open-label, two-arm, randomized (1:1) clinical demonstration project to determine if the use of a text-message based adherence intervention (iTAB) improves retention and adherence to PrEP compared to standard of care (SoC) PrEP delivery.


Options:
A: N/A
B: Arm Label: Text-Based Adherence Game; Type: EXPERIMENTAL; Interventions: Behavioral: Text-Based Adherence Game, Behavioral: Standard of Care (SOC) | Arm Label: Standard of Care (SOC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard of Care (SOC) | Intervention Type: BEHAVIORAL; Name: Text-Based Adherence Game; Assigned to Arm(s): Text-Based Adherence Game | Intervention Type: BEHAVIORAL; Name: Standard of Care (SOC); Assigned to Arm(s): Standard of Care (SOC), Text-Based Adherence Game
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: CHW-Visit; Type: EXPERIMENTAL; Interventions: Behavioral: Delivery of a Post-Partum Package | Arm Label: CHW-Phone; Type: EXPERIMENTAL; Interventions: Behavioral: Delivery of a Post-Partum Package | Intervention Type: BEHAVIORAL; Name: Delivery of a Post-Partum Package; Assigned to Arm(s): CHW-Phone, CHW-Visit
D: Arm Label: Standard of Care (SoC); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SoC + iTab; Type: ACTIVE_COMPARATOR; Interventions: Device: SoC + iTab | Intervention Type: DEVICE; Name: SoC + iTab; Assigned to Arm(s): SoC + iTab

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Protecting Pregnant Women From Infectious Diseases: a Cluster Randomized Evaluation of the Comprehensive "P3" Intervention Package Within Obstetric Practices in Georgia
Brief Summary: The primary research aim of this project is to test the effectiveness of a comprehensive, evidence-based vaccine promotion package implemented in the obstetric setting on increasing the likelihood that a pregnant woman in Georgia will receive an influenza and/or pertussis vaccine.


Options:
A: Arm Label: Group A; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Community mobilization | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Community mobilization, Biological: Combined Oral Polio Vaccine and Inject able Polio Vaccine during SIA | Intervention Type: BEHAVIORAL; Name: Enhanced Community mobilization; Assigned to Arm(s): Group B, Group C | Intervention Type: BIOLOGICAL; Name: Combined Oral Polio Vaccine and Inject able Polio Vaccine during SIA; Assigned to Arm(s): Group C
B: Arm Label: P3 Vaccine Promotion Package; Type: EXPERIMENTAL; Interventions: Behavioral: P3 Vaccine Promotion Package. | Arm Label: No P3 vaccine promotion package intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: P3 Vaccine Promotion Package.; Assigned to Arm(s): P3 Vaccine Promotion Package
C: Arm Label: Participatory; Type: EXPERIMENTAL; Interventions: Behavioral: Participatory | Arm Label: Efficient; Type: EXPERIMENTAL; Interventions: Behavioral: Efficient | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Participatory; Assigned to Arm(s): Participatory | Intervention Type: BEHAVIORAL; Name: Efficient; Assigned to Arm(s): Efficient
D: Arm Label: Intervention Clinics; Type: EXPERIMENTAL; Interventions: Behavioral: Academic Detailing | Arm Label: Control Clinics; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Academic Detailing; Assigned to Arm(s): Intervention Clinics

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Continuous renal replacement therapy (CRRT) has been considered as an effective modality for renal replacement therapy in hemodynamically unstable patients within intensive care unit (ICU) except for the necessity of anticoagulation. The severity and peculiarities of ICU patients often make it equivocal to use anticoagulation. This is a prospective randomized controlled study to show the difference in filter life span and adverse event between HF1000 (nafamostat mesilate) group and M100 (heparin-free) group.


Options:
A: Arm Label: CVVH using oXiris™ filter; Type: EXPERIMENTAL; Interventions: Biological: Arterial blood sampling, Biological: Ultrafiltrate sampling, Device: CVVH using oXiris™ filter | Arm Label: CVVH using PrismafleX HF1400 filter; Type: ACTIVE_COMPARATOR; Interventions: Biological: Arterial blood sampling, Biological: Ultrafiltrate sampling, Device: CVVH using PrismafleX HF1400 filter | Intervention Type: BIOLOGICAL; Name: Arterial blood sampling; Assigned to Arm(s): CVVH using PrismafleX HF1400 filter, CVVH using oXiris™ filter | Intervention Type: BIOLOGICAL; Name: Ultrafiltrate sampling; Assigned to Arm(s): CVVH using PrismafleX HF1400 filter, CVVH using oXiris™ filter | Intervention Type: DEVICE; Name: CVVH using oXiris™ filter; Assigned to Arm(s): CVVH using oXiris™ filter | Intervention Type: DEVICE; Name: CVVH using PrismafleX HF1400 filter; Assigned to Arm(s): CVVH using PrismafleX HF1400 filter
B: Arm Label: 1 prostacyclin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: prostacyclin | Arm Label: 2 heparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: heparin | Intervention Type: DRUG; Name: prostacyclin; Assigned to Arm(s): 1 prostacyclin group | Intervention Type: DRUG; Name: heparin; Assigned to Arm(s): 2 heparin group
C: Arm Label: Femoral route; Type: EXPERIMENTAL; Interventions: Procedure: Femoral route for hemodialysis | Arm Label: Jugular route; Type: EXPERIMENTAL; Interventions: Procedure: Jugular route for hemodialysis | Intervention Type: PROCEDURE; Name: Femoral route for hemodialysis; Assigned to Arm(s): Femoral route | Intervention Type: PROCEDURE; Name: Jugular route for hemodialysis; Assigned to Arm(s): Jugular route
D: Arm Label: M100; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anticoagulation with nafamostat mesilate | Arm Label: HF1000; Type: EXPERIMENTAL; Interventions: Drug: Anticoagulation with nafamostat mesilate | Intervention Type: DRUG; Name: Anticoagulation with nafamostat mesilate; Assigned to Arm(s): HF1000, M100

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Continuous renal replacement therapy (CRRT) has been considered as an effective modality for renal replacement therapy in hemodynamically unstable patients within intensive care unit (ICU) except for the necessity of anticoagulation. The severity and peculiarities of ICU patients often make it equivocal to use anticoagulation. This is a prospective randomized controlled study to show the difference in filter life span and adverse event between HF1000 (nafamostat mesilate) group and M100 (heparin-free) group.


Options:
A: Arm Label: Dilute heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dilute unfractionated heparin | Arm Label: Standard concentrated heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard concentration unfractionated heparin | Intervention Type: DRUG; Name: Dilute unfractionated heparin; Assigned to Arm(s): Dilute heparin | Intervention Type: DRUG; Name: Standard concentration unfractionated heparin; Assigned to Arm(s): Standard concentrated heparin
B: Arm Label: M100; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anticoagulation with nafamostat mesilate | Arm Label: HF1000; Type: EXPERIMENTAL; Interventions: Drug: Anticoagulation with nafamostat mesilate | Intervention Type: DRUG; Name: Anticoagulation with nafamostat mesilate; Assigned to Arm(s): HF1000, M100
C: Arm Label: RCA Group; Type: EXPERIMENTAL; Interventions: Drug: Anticoagulation to prevent clotting of the extracorporeal circuit. (regional citrate anticoagulation) | Arm Label: Heparin group; Type: EXPERIMENTAL; Interventions: Drug: Anticoagulation to prevent clotting of the extracorporeal circuit (Unfractionated heparin) | Intervention Type: DRUG; Name: Anticoagulation to prevent clotting of the extracorporeal circuit. (regional citrate anticoagulation); Assigned to Arm(s): RCA Group | Intervention Type: DRUG; Name: Anticoagulation to prevent clotting of the extracorporeal circuit (Unfractionated heparin); Assigned to Arm(s): Heparin group
D: Arm Label: Heparin lock; Type: PLACEBO_COMPARATOR; Interventions: Drug: unfractionated heparin | Arm Label: Citrate lock; Type: EXPERIMENTAL; Interventions: Drug: Citrate 4% | Intervention Type: DRUG; Name: Citrate 4%; Assigned to Arm(s): Citrate lock | Intervention Type: DRUG; Name: unfractionated heparin; Assigned to Arm(s): Heparin lock

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Continuous renal replacement therapy (CRRT) has been considered as an effective modality for renal replacement therapy in hemodynamically unstable patients within intensive care unit (ICU) except for the necessity of anticoagulation. The severity and peculiarities of ICU patients often make it equivocal to use anticoagulation. This is a prospective randomized controlled study to show the difference in filter life span and adverse event between HF1000 (nafamostat mesilate) group and M100 (heparin-free) group.


Options:
A: Arm Label: heparin anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Arm Label: citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Drug: Citrate | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): heparin anticoagulation | Intervention Type: DRUG; Name: Citrate; Assigned to Arm(s): citrate anticoagulation
B: Arm Label: Nafamostat mesilate group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nafamostat mesilate | Arm Label: No anticoagulation group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Nafamostat mesilate; Assigned to Arm(s): Nafamostat mesilate group | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): No anticoagulation group
C: Arm Label: M100; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anticoagulation with nafamostat mesilate | Arm Label: HF1000; Type: EXPERIMENTAL; Interventions: Drug: Anticoagulation with nafamostat mesilate | Intervention Type: DRUG; Name: Anticoagulation with nafamostat mesilate; Assigned to Arm(s): HF1000, M100
D: Arm Label: heparinized saline priming group; Type: EXPERIMENTAL; Interventions: Drug: heparinized saline priming group | Arm Label: nafamostat infusion group after heparinized saline priming; Type: ACTIVE_COMPARATOR; Interventions: Drug: nafamostat infusion after heparinized saline priming | Intervention Type: DRUG; Name: heparinized saline priming group; Assigned to Arm(s): heparinized saline priming group | Intervention Type: DRUG; Name: nafamostat infusion after heparinized saline priming; Assigned to Arm(s): nafamostat infusion group after heparinized saline priming

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TEA (Together for Empowerment Activities)for Families and Children: A Randomized Intervention Trial
Brief Summary: The impact of HIV/AIDS is negatively influencing the affected families and their next generation. HIV is radiating through the extended families, shifting the life patterns not only for the parents living with HIV/AIDS (PLH), but also for their children, partners, and other family members. To help PLHs and their family members, the TEA intervention has been developed, refined and piloted in the previous study. The goal of this study is to implement the TEA intervention in a full scale to determine its efficacy and the potential for enhancing HIV policy and programs that support HIV-affected families to cope with the challenges in China in responding to the global HIV epidemic.


Options:
A: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Behavioral: The TEA intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: The TEA intervention; Assigned to Arm(s): intervention
B: Arm Label: Comparison; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: HIV prevention intervention; Type: EXPERIMENTAL; Interventions: Behavioral: HIV prevention intervention | Intervention Type: BEHAVIORAL; Name: HIV prevention intervention; Assigned to Arm(s): HIV prevention intervention
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Psychosocial support training for school teachers | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychosocial support training for school teachers; Assigned to Arm(s): Intervention
D: Arm Label: Soccer League (SL); Type: EXPERIMENTAL; Interventions: Behavioral: Soccer League (SL) | Arm Label: Soccer League/Vocational Training (SL-V); Type: EXPERIMENTAL; Interventions: Behavioral: Soccer League/Vocational Training (SL-V) | Arm Label: Control Condition (CC); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Soccer League (SL); Assigned to Arm(s): Soccer League (SL) | Intervention Type: BEHAVIORAL; Name: Soccer League/Vocational Training (SL-V); Assigned to Arm(s): Soccer League/Vocational Training (SL-V)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50/250mcg Twice Daily Alone or ADOAIR 50/250mcg Plus Tiotropium Bromide 18mcg
Brief Summary: The purpose of this study is to assess the control of COPD using a symptom and exacerbation risk based treatment strategy based on GOLD 2011. This study is conducted in Japanese subjects with COPD and assess whether the GOLD 2011 strategy is effective in medical practice in Japan.


Options:
A: Arm Label: ADVAIR DISKUS® inhlaer Plus SPIRIVA® HANDIHALER® inhaler; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Propionate/Salmeterol | Arm Label: SPIRIVA® HANDIHALER® inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium Bromide | Intervention Type: DRUG; Name: Tiotropium Bromide; Assigned to Arm(s): SPIRIVA® HANDIHALER® inhaler | Intervention Type: DRUG; Name: Fluticasone Propionate/Salmeterol; Assigned to Arm(s): ADVAIR DISKUS® inhlaer Plus SPIRIVA® HANDIHALER® inhaler
B: Intervention Type: DRUG; Name: Tiotropium + SERETIDE 50/500; Assigned to Arm(s): N/A
C: Arm Label: Symbicort+TIO; Type: ACTIVE_COMPARATOR; Interventions: Drug: Symbicort (budesonide/formoterol turbuhaler 320/9ug) | Arm Label: Spiriva® + Placebo Turbuhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spiriva (tiotropium bromide 18ug) | Intervention Type: DRUG; Name: Symbicort (budesonide/formoterol turbuhaler 320/9ug); Assigned to Arm(s): Symbicort+TIO | Intervention Type: DRUG; Name: Spiriva (tiotropium bromide 18ug); Assigned to Arm(s): Spiriva® + Placebo Turbuhaler
D: Arm Label: fluticasone propionate/salmeterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate/salmeterol 50/250mcg, Drug: tiotropium bromide placebo, Drug: fluticasone propionate/salmeterol 50/250mcg and tiotropium 18mcg | Arm Label: tiotropium bromide; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate/salmeterol placebo, Drug: tiotropium bromide 18mcg, Drug: fluticasone propionate/salmeterol 50/250mcg and tiotropium 18mcg | Intervention Type: DRUG; Name: fluticasone propionate/salmeterol 50/250mcg; Assigned to Arm(s): fluticasone propionate/salmeterol | Intervention Type: DRUG; Name: fluticasone propionate/salmeterol placebo; Assigned to Arm(s): tiotropium bromide | Intervention Type: DRUG; Name: tiotropium bromide 18mcg; Assigned to Arm(s): tiotropium bromide | Intervention Type: DRUG; Name: tiotropium bromide placebo; Assigned to Arm(s): fluticasone propionate/salmeterol | Intervention Type: DRUG; Name: fluticasone propionate/salmeterol 50/250mcg and tiotropium 18mcg; Assigned to Arm(s): fluticasone propionate/salmeterol, tiotropium bromide

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Influence of Training With Whole Body Vibration Device (Galileo) on Quality of Life (QoL), Exercise Capacity, as Well as on the Effects of Muscle Power and Muscle Function in Patients With Pulmonal Arterial Hypertension (PAH). (GALILEO PAH)
Brief Summary: Title of study / project: Influence of training with whole body vibration device on Quality of Life (QoL), exercise capacity, as well as on the effects of muscle power and muscle function in patients with pulmonal arterial hypertension (PAH). Background and rationale for the proposal:Capacity and the ability to exercise, in patients with PAH is limited. There is a few investigations evaluating the effects of the training with whole body vibration (wbv) in adults. It was shown that wbv-training could improve muscle power, QoL, body balance and had positive effects on the neuromuscular system. Primary scientific question addressed:Changes in muscle power, changes in 6-Minute Walk Distance (6MWD) and changes in QoL are to be evaluated.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Aerobic exercise | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Aerobic exercise | Intervention Type: OTHER; Name: Aerobic exercise; Assigned to Arm(s): 1, 2
B: Arm Label: Training Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Upper extremity aerobic exercise training | Arm Label: Control Group; Type: SHAM_COMPARATOR; Interventions: Other: Alternative upper extremity exercises | Intervention Type: OTHER; Name: Upper extremity aerobic exercise training; Assigned to Arm(s): Training Group | Intervention Type: OTHER; Name: Alternative upper extremity exercises; Assigned to Arm(s): Control Group
C: N/A
D: Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: N/A | Arm Label: Exercise Group Galileo PAH; Type: ACTIVE_COMPARATOR; Interventions: Device: Exercise Group Galileo PAH | Intervention Type: DEVICE; Name: Exercise Group Galileo PAH; Assigned to Arm(s): Exercise Group Galileo PAH

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Secondary Stroke Prevention by Uniting Community and Chronic Care Model Teams Early to End Disparities: the SUCCEED Trial
Brief Summary: The purpose of this study is to test a newly-developed outpatient clinic and community-based care intervention called SUCCEED (Secondary stroke prevention by Uniting Community and Chronic care model teams Early to End Disparities) for improving control of stroke risk factors among stroke patients in the Los Angeles County "safety net", and to measure the costs of running such an intervention, relative to usual care.


Options:
A: Arm Label: Arm 1 Telemedicine Outreach for PTSD; Type: EXPERIMENTAL; Interventions: Other: Telemedicine Outreach for PTSD | Arm Label: Arm 2 Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Telemedicine Outreach for PTSD; Assigned to Arm(s): Arm 1 Telemedicine Outreach for PTSD
B: Arm Label: Comprehensive Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle Changes, Drug: Antiplatelet Agents, Drug: Beta Blocker, Drug: ACE Inhibitors | Arm Label: Less Intensive Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle Changes | Intervention Type: BEHAVIORAL; Name: Lifestyle Changes; Assigned to Arm(s): Comprehensive Intervention Group, Less Intensive Intervention Group | Intervention Type: DRUG; Name: Antiplatelet Agents; Assigned to Arm(s): Comprehensive Intervention Group | Intervention Type: DRUG; Name: Beta Blocker; Assigned to Arm(s): Comprehensive Intervention Group | Intervention Type: DRUG; Name: ACE Inhibitors; Assigned to Arm(s): Comprehensive Intervention Group
C: Arm Label: Care Management+Community Health Worker; Type: EXPERIMENTAL; Interventions: Behavioral: Care Management+Community Health Worker | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Care Management+Community Health Worker; Assigned to Arm(s): Care Management+Community Health Worker | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Pharmacist Intervention for Low-Literacy in Cardiovascular Disease | Intervention Type: BEHAVIORAL; Name: Pharmacist Intervention for Low-Literacy in Cardiovascular Disease; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Secondary Stroke Prevention by Uniting Community and Chronic Care Model Teams Early to End Disparities: the SUCCEED Trial
Brief Summary: The purpose of this study is to test a newly-developed outpatient clinic and community-based care intervention called SUCCEED (Secondary stroke prevention by Uniting Community and Chronic care model teams Early to End Disparities) for improving control of stroke risk factors among stroke patients in the Los Angeles County "safety net", and to measure the costs of running such an intervention, relative to usual care.


Options:
A: Arm Label: group 1: standard physiotherapy; Type: PLACEBO_COMPARATOR; Interventions: Procedure: standard physiotherapy | Arm Label: group 2: experimental physiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: experimental physiotherapy | Intervention Type: PROCEDURE; Name: standard physiotherapy; Assigned to Arm(s): group 1: standard physiotherapy | Intervention Type: PROCEDURE; Name: experimental physiotherapy; Assigned to Arm(s): group 2: experimental physiotherapy
B: Arm Label: Care Management+Community Health Worker; Type: EXPERIMENTAL; Interventions: Behavioral: Care Management+Community Health Worker | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Care Management+Community Health Worker; Assigned to Arm(s): Care Management+Community Health Worker | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Arm Label: Arm 1; Type: OTHER; Interventions: Behavioral: Exercise | Arm Label: Arm 2; Type: OTHER; Interventions: Other: Stroke education | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: Stroke education; Assigned to Arm(s): Arm 2
D: Arm Label: Exercise recommendation; Type: EXPERIMENTAL; Interventions: Other: Aerobic exercise | Arm Label: Aerobic exercise; Type: EXPERIMENTAL; Interventions: Other: Aerobic exercise | Intervention Type: OTHER; Name: Aerobic exercise; Assigned to Arm(s): Aerobic exercise, Exercise recommendation

Answer: B